14. External Validity ECM III-IV/ Color Group: Grey/ Fall 2009 Is this study generalizable to our patient? Yes! Note: most patients in the study had intermediate uveitis, therefore the study is most generalizable to patients with this form of the disease Study Our Patient Age Average: 36 y.o. 39 y.o. Duration of uveitis Median: 48 months (range= 6 months-10 yrs) 10 years Pre-operative therapy Coricosteroids (80%) Immunosuppress. (30%) Corticosteroids immunosuppresants
![Case Background (HPI) ,[object Object],ECM III-IV/ Color Group: Grey/ Fall 2009](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)